酶激活式抗肿瘤前体药物的研究进展
摘要
酶激活式抗肿瘤前体药物利用特异表达于肿瘤组织的酶激活本无活性的前体药物而发挥靶向肿瘤细胞的细胞毒作用。本文根据肿瘤组织自身表达酶的部位、种类、结构、功能和性质的不同,阐述了现有几种酶激活式前体药物的工作原理和研究现状,比较了该类前药与人工引入酶激活式前药的优劣,评价其发展前景。
出处
《华西药学杂志》
CAS
CSCD
北大核心
2007年第5期536-538,共3页
West China Journal of Pharmaceutical Sciences
基金
国家自然科学基金资助项目(批准号:30471978)
广东省自然基金资助课题(批准号:5001771)
参考文献15
-
1Hyo- Kyung Hart, Gordon L Amidon. Targeted Prodrug Design to Optimize Drug Delivery [ J ]. AAPS Pharmsci, 2000,2 ( 1 ) : 1 -11.
-
2Guang Xu, Howard L McLeod. Strategies for Enzyme/Prodrug Cancer Therapy[ J]. Clinical Cancer Research,2001,7 : 3314 - 3324.
-
3Deborah DeFeo-Jones, Stephen F Brady, Dong- Mei Feng, et al. A Prostate - specific Antigen (PSA) - activated Vinblastine Prodrug Selectively Kills PSA - secreting Cells in vivo [ J ]. Molecular Cancer Therapeutics,2002, 1 : 451 - 459.
-
4Deborah Defeo -jones, Victor m Garsky. A peptide - doxorubicin 'predrug' activated by prostate specific antigen selectively kills prostate tumor eells positive for prostate - speeifie antigen in vivo[J]. Nature Medeine,2000, 6( 11 ) :1248 - 1252.
-
5Samuel R Denmeade, Carsten M Jakobsen , Samuel J, et al. Prostate - specific antigen - activated thapsigargin prodrug as targeted therapy for prostate cancer [ J ]. Nat Can Insti, 2003, 95 (13) : 990 - 1000.
-
6李斌,郝晓柯,苏明权.PSA激活的前体药物疗法治疗前列腺癌研究进展[J].中国肿瘤生物治疗杂志,2004,11(2):154-156. 被引量：4
-
7Robert S DiPaola, John R, John N, et al. Characterization of a Novel Prostate - Specific - Antigen - Activated Peptide - Doxorubicin Conjugate in Patients With Prostate Cancer [ J ]. J Clin Onco,2002, 20 ( 7 ) : 1874 - 1879.
-
8Sounni N E. Membrane type - matrix metalloproteinases and tumor progression[ J]. Biochimie 2005,87 : 329 - 342.
-
9Ahmed M Mansour, Joachim Drevs, Norbert Esser, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin - binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2 [ J ]. Can Res, 2003, 63:4062 - 4066.
-
10Toni Kline, Michael Y Torgov, Brian A Mendelsohn, et al. Novel Antitumor Prodrugs Designed for Activation by Matrix Metalloproteinases - 2 and - 9 [ J ]. Mole Pharma,2003, 1 ( 1 ) :9 - 22.
二级参考文献16
-
1Deborah DJ, Grasky VM, Wong BK, et al. A peptide-doxorubicin prodrug activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo[ J]. Nat Med, 2000, 6(11): 1248-1252.
-
2Brady SF, Pawluczyk JM, Lumma PK, et al. Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity [ J ]. J Med Chem, 2002, 45: 4706-4715.
-
3Schwartz MS, Matuszewski BK. Determination of a peptide-doxorubicin antigen activated prodrug, and its active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection stabilization of the peptide prodrug with ED
-
4Denmeade SR, Sokoll LJ, Chan DW, et al. Concentration of enzymatically active prostate-specific antigen( PSA ) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models[J]. Prostate, 2001,48( 1 ): 1-6.
-
5Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003[J]. CA, 2003, 53(1): 5-26.
-
6Robert SD, John R, John N, et al. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer [ J ]. J Clin Oncol, 2002, 20 ( 7 ):1874-1879.
-
7Grasky VM, Lumma PK, Feng DM, et al. The synthesis of a prodrug of doxorubicin designed to provide reduce systemic toxicity and greater target efficacy[J]. J Med Chem, 2001, 44(24): 4216-4224.
-
8Deborah DJ, Brady SF, Feng DM, et al. A prostate-specific antigen (PSA) -activated vinblastine prodrug selectively kills PSA-secreting cells in vivo[J]. Mol Cancer Ther, 2002, 1 (7): 451-459.
-
9Mhaka A, Denmeade SR, Yao W, et al. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer [ J ]. Bioorg Med Chem Lett, 2002, 12(17): 2459-2461.
-
10Bradley KW, Deborah DJ, Raymond EJ, et al. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites [ J]. Drug Metab Dispos,2001, 29: 313-318.
共引文献3
-
1李斌,郝晓柯,李立文,苏明权.抗前列腺癌多肽APP216的体外活性[J].中国肿瘤生物治疗杂志,2006,13(3):205-208. 被引量：1
-
2李斌,郝晓柯,李立文,苏明权.特异性抗前列腺癌多肽抑制前列腺癌细胞生长的作用研究[J].中国癌症杂志,2007,17(1):41-45.
-
3刘兴奋,华笑笑,黄艳琴,冯晓苗,范曲立,黄维.基于水溶性共轭聚合物分子刷的肿瘤标志物快速检测[J].化学通报,2015,78(10):895-901. 被引量：1
-
1田华,黄仁鹏,靳占峰,付志军.成纤维细胞激活蛋白和转化生长因子-β1在小鼠肝纤维化组织中的表达及相关性[J].肝脏,2009,14(6):454-457. 被引量：3
-
2英车科学家研制消除毒瘤新药获突破[J].国际医药卫生导报,2001,7(11B):25-25.
-
3非甾体类抗炎药与前列腺特异性抗原和前列腺体积的关系[J].中华泌尿外科杂志,2009,30(9):608-608.
-
4曾冲,朱树雄.APSAC干预死亡率研究[J].岭南心血管病杂志,2003,9(2):120-120.
-
5邓媛媛,徐俊,杨倩之,蔡绍晖.成纤维细胞激活蛋白α与肿瘤微环境的免疫抑制[J].华西药学杂志,2012,27(4):455-457. 被引量：1
-
6Andriole GL,Bostwick DG,Brawley OW.度他雄胺:可能降低前列腺癌发病风险[J].中国处方药,2010,9(4):63-63.
-
7徐科伟.戈舍瑞林针剂治疗晚期前列腺癌77例临床观察[J].海峡药学,2013,25(5):203-204. 被引量：4
-
8孟露娜.补充抗氧化维生素和矿物质可预防前列腺癌[J].国外医学情报,2005,26(10):38-39.
-
9梁小兵,张姝,禤彩云,许文,张杰.成纤维细胞激活蛋白在肝纤维化模型大鼠肝组织中的动态表达[J].药物评价研究,2015,38(3):284-287.
-
10张贤生,王益鑫,李铮,冷静,白强,黄旭元,黄翼然.小剂量生长激素补充在中老年男性中的应用研究[J].中华男科学杂志,2004,10(8):601-603. 被引量：4
